These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35613248)

  • 1. Anatomy of the first six months of COVID-19 vaccination campaign in Italy.
    Gozzi N; Chinazzi M; Davis JT; Mu K; Pastore Y Piontti A; Ajelli M; Perra N; Vespignani A
    PLoS Comput Biol; 2022 May; 18(5):e1010146. PubMed ID: 35613248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An agent-based model to assess large-scale COVID-19 vaccination campaigns for the Italian territory: The case study of Lombardy region.
    Cattaneo A; Vitali A; Mazzoleni M; Previdi F
    Comput Methods Programs Biomed; 2022 Sep; 224():107029. PubMed ID: 35908330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran.
    Ghafari M; Hosseinpour S; Rezaee-Zavareh MS; Dascalu S; Rostamian S; Aramesh K; Madani K; Kordasti S
    BMC Med; 2023 Nov; 21(1):429. PubMed ID: 37953291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A flexible age-dependent, spatially-stratified predictive model for the spread of COVID-19, accounting for multiple viral variants and vaccines.
    Schneider KA; Tsoungui Obama HCJ; Adil Mahmoud Yousif N
    PLoS One; 2023; 18(1):e0277505. PubMed ID: 36662784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Effectiveness of Global COVID-19 Vaccination Campaign.
    He D; Ali ST; Fan G; Gao D; Song H; Lou Y; Zhao S; Cowling BJ; Stone L
    Emerg Infect Dis; 2022 Sep; 28(9):1873-1876. PubMed ID: 35914516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
    COVID-19 Forecasting Team
    Lancet; 2022 Apr; 399(10334):1469-1488. PubMed ID: 35219376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign.
    Papini F; Grassi N; Guglielmi G; Gattini V; Rago L; Bisordi C; Scateni M; Totaro M; Tulipani A; Porretta A; Tavoschi L; Guercini J; Luchini G; Briani S; Privitera GP; Baggiani A
    Environ Health Prev Med; 2021 Sep; 26(1):99. PubMed ID: 34592930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
    COVID-19 National Preparedness Collaborators
    Lancet; 2022 Apr; 399(10334):1489-1512. PubMed ID: 35120592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparities in access to COVID-19 vaccine in Verona, Italy: a cohort study using local health immunization data.
    Benoni R; Sartorello A; Moretti F; Marchiori F; Accordini L; Postiglione C; Coffele V; Tardivo S
    Front Public Health; 2023; 11():1167414. PubMed ID: 37397767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.
    Brault A; Hart A; Uribe P; Prado J; San Martín J; Maass A; Canals M
    BMC Infect Dis; 2024 May; 24(1):467. PubMed ID: 38698324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
    Giordano G; Colaneri M; Di Filippo A; Blanchini F; Bolzern P; De Nicolao G; Sacchi P; Colaneri P; Bruno R
    Nat Med; 2021 Jun; 27(6):993-998. PubMed ID: 33864052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Ferreira LS; de Almeida GB; Borges ME; Simon LM; Poloni S; Bagattini ÂM; da Rosa MQM; Diniz Filho JAF; Kuchenbecker RS; Camey SA; Kraenkel RA; Coutinho RM; Toscano CM
    Vaccine; 2022 Nov; 40(46):6616-6624. PubMed ID: 36210250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
    Lytras T; Kontopidou F; Lambrou A; Tsiodras S
    J Med Virol; 2022 Oct; 94(10):5044-5050. PubMed ID: 35701379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
    Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
    BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.